CA-TREASURE-DATA
8.10.2020 14:02:14 CEST | Business Wire | Press release
Treasure Data ™ today unveiled its Global Partner Program , offering agencies, consultancies, technology service providers, independent software vendors (ISVs) and data specialists new certifications, training, and technical, marketing and sales support for the Company’s market-leading Customer Data Platform (CDP). The program will be launching with 20 strategically selected partners and is set to grow as we continue to expand our customer base in all territories.
“Enterprises are turning to trusted partners in their respective industries to accelerate customer-centric digital transformation and solve complex data, scale and other obstacles that hinder exceptional brand experiences,” said Stephen Lee, Vice President of Strategy and Business Development, Treasure Data. “Treasure Data’s Global Partner Program helps trusted enterprise partners expand their CDP technical acumen and experience to grow their market and revenue opportunities.”
Certified Partners help customers throughout their entire CDP deployment journey. For agencies, and consultancies, the program offers three tiers—bronze, silver and gold—with level-specific commitments for online training, joint marketing, market development funds (MDF), discounts, and technical and sales support. In addition to access to Treasure Data’s CDP Academy training, partners may also receive additional certified sales and technical training matched to key roles ranging from sales and marketing operations to data architects and scientists. The program is also open to select Treasure Data technology partners.
“Acxiom and its partners strive to drive transformational change for clients through strategic partnerships and we’re excited to be working with such a powerful tool as the Treasure Data CDP,” says Mike Menzer, President, Acxiom International. “Customer Data Platforms are creating a lot of growth right now and we see the Acxiom and Treasure Data combination as a key solution to driving value for our clients.”
“CDPs like Treasure Data are playing an increasingly important role in helping marketers better understand who their customers are,” says Jayne Babine, Executive Vice President, Partnerships and Sales at MightyHive. “As one of the leading full-service global marketing services firms, MightyHive is thrilled to be partnering with Treasure Data to make our clients more successful around data marketing strategy and execution.”
Treasure Data’s CDP unifies and unlocks the full potential of customer data. It captures all online and offline customer interactions as they happen, helping companies to understand all brand interactions with the precise detail needed to engage customers at the right time in the right place. Trusted by more than 400 organizations worldwide, Treasure Data provides an enterprise-scale, independent solution that lets partners work with any existing technology stack and gives them the flexibility to ingest all types of data. This makes it easy to integrate the Treasure Data CDP with partner offerings and preferred solutions stacks to accelerate the delivery of outstanding, personalized data-driven brand experiences.
Partners included in Treasure Data’s Global Partner Program: Accenture, Acxiom, MightyHive in the Gold Tier. Allant, BitBang, Brain+Trust Partners, Merkle (Isobar, Sokrati) Search Discovery, SilverBullet in the Silver Tier. AdGlobal360, Ansira, Exostatic, Gravitai, Green Lyzard, HGS Digital, Hero Digital, Hexagon Data, Keyrus, Verticurl in the Bronze Tier. For more information on our partner program, please visit https://www.treasuredata.com/partnerships/
About Treasure Data
Treasure Data Customer Data Platform (CDP) empowers enterprises by delivering rich insights that drive outstanding customer experiences. Built on a strong data management foundation, our CDP enables brands to securely unify customer data across silos at scale so they can better identify, engage and acquire customers. The highly configurable platform boasts a comprehensive connector network that evolves with your existing technology stack to future-proof all customer data initiatives. Treasure Data has more than 400 customers including Fortune 500 and Global 2000 enterprises, and is a wholly-owned subsidiary of Arm Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom